Transthyretin Amyloid Cardiomyopathy

Promising new treatments for cardiac amyloidosis are expected in the near future. Cardiac amyloidosis (CA) results from the deposition of misfolded proteins in the cardiac tissue. Its two main forms are light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR), further classified as familial (vATTR) and wild-type (wtATTR). The treatments for AL, wtATTR, and vATTR differ...

Knowledge of red flags suggesting cardiac transthyretin amyloidosis is crucial for identifying at-risk patients and establishing the correct diagnosis. Cardiac amyloidosis is caused by the extracellular deposition of misfolded proteins in cardiac tissue. Wild-type transthyretin amyloidosis (wtATTR) is the most common form of cardiac amyloidosis. It mostly affects elderly patients, who usually present with heart...

Cardiac amyloidosis, particularly wild-type transthyretin amyloidosis, is often underdiagnosed, affecting mainly elderly men. Recognizing red flags suggestive of wild-type transthyretin amyloidosis is important for timely diagnosis and allows patients to benefit from effective therapies. Cardiac amyloidosis is a group of diseases characterized by extracellular deposition of misfolded proteins in the heart. Three types of amyloidosis...

A recent study develops a more efficient model to assess the likelihood of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure (HF), improving early identification and potential treatment for this underrecognized condition. The propensity model developed in the study demonstrated a 71.9% sensitivity and 95.2% specificity in identifying patients with HF who are more...

Recent advances in gene-silencing and gene-editing therapies have demonstrated significant potential in altering the treatment landscape for transthyretin (TTR) amyloidosis, transforming the disease’s perception from universally progressive and fatal to treatable with highly specific and effective therapies. Gene-silencing and gene-editing therapies have led to substantial improvement in outcomes for patients with ATTR polyneuropathy. Small-scale studies...

ATTR-CM treatment is difficult, in most cases, but diflunisal is a promising treatment option for wild-type ATTR-CM. Treatment options for transthyretin amyloid cardiomyopathy (ATTR-CM) have historically been either risky or lacking in long-term efficacy. Treating ATTR-CM is, in most cases, significantly improved when it is discovered early, although this poses some unique challenges of its...

Diagnosing ATTR-CM is usually a difficult and potentially dangerous process, but non-invasive novel modalities could significantly reduce the risk. Transthyretin amyloid cardiomyopathy (ATTR-CM) is an infiltrative disease characterized by deposits of amyloid fibrils. It tends to have high morbidity, poor treatment outcomes, and high treatment expenditure. Recent advances in therapeutic strategies for ATTR-CM have shown...

ATTR-CM can only be treated in a limited number of ways, and this article analyzes and compares the currently available treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, debilitating disease with high mortality. ATTR-CM is caused by transthyretin (TTR) amyloid protein build ups in the myocardium and other organs, in most cases the peripheral...

With a minimal incidence of amyloid recurrence in the cardiac allograft, cardiac transplantation is well tolerated, increases functional ability, and lengthens survival in patients with ATTR-CM, according to a 30-year retrospective study. ATTR-CM should be included in the list of transplantation indications. Cardiomyopathy caused by transthyretin amyloidosis cardiomyopathy (ATTR-CM) is progressive and fatal. Patients with...